TABLE 1.

Solid-phase, SPA binding and inhibition of cell adhesion of integrin antagonists MN27, DS-70 and SR714 to VCAM-1 or ICAM-1 (2 μg/mL) (Baiula et al., 2016; Dattoli et al., 2018).

Integrin antagonists	Solid-phase binding/SPA a IC50 (nM)	Cell adhesion b Jurkat, α4β1/VCAM-1 IC50 (nM)	Cell adhesion b Jurkat, αLβ2/ICAM-1 IC50 (nM)
MN27 (αLβ2)	6.7 ± 2.5 (αLβ2)	574.0 ± 1.7	0.39 ± 0.02
DS-70 (α4β1)	8.3 ± 3.2 (α4β1)	5.04 ± 0.51	>5000
SR714 (α4β1)	1.1 ± 0.1 (α4β1)	1.39 ± 0.04	>5000

^aIC₅₀ values of β-lactam compounds and DS-70 on leukocyte integrins determined by a competitive solid-phase binding assay to specific ligand (ICAM-1 for α_Lβ₂) or by scintillation proximity assay (SPA, FN for α₄β₁). Six independent experiments were run in quadruplicate. Data are expressed as means ± SD (Baiula et al., 2016; Dattoli et al., 2018).

^bIn a cell-based assay, the adhesion of a cell line preferentially expressing a specific integrin heterodimer to an immobilized adhesion molecule was measured. Six independent experiments were run in quadruplicate. Data are expressed as means ± SD (Baiula et al., 2016; Dattoli et al., 2018).